Prescription medicine
Glipizide and metformin First approved as Metaglip
Glipizide and metformin (Metaglip) is a prescription medicine with an FDA approval on record since 2002. FDA's NDC Directory lists it from 9 generic labelers, and pharmacies paid $0.242 per unit (Glipizide-metformin 2.5-250 mg) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the glipizide and metformin FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.); the NDA 21460 record on Drugs@FDA; every glipizide and metformin label on DailyMed.
Highlights of the record
FDA label of June 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageGlipizide and metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Forms and strengths
- 2.5 mg / 500 mg
- 2.5 mg / 250 mg
- 5 mg / 500 mg
Film-coated tablet.
On the market
- Earliest approval on file
- October 21, 2002 Metaglip, Bristol Myers Squibb; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 6 first October 27, 2005; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 9 of which 9 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.242 per unit Glipizide-metformin 2.5-250 mg
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2015 0 Class I among all firms' recalls; latest March 25, 2015
- FAERS reports
- 82 through July 30, 2026
What is glipizide and metformin used for?
From the label: indications and usageGlipizide and metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Conditions named in the indications of glipizide and metformin's FDA labels, with every medicine labeled for each:
From other glipizide and metformin labelsType 2 diabetes: INDICATIONS AND USAGE Glipizide and metformin hydrochloride tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FDA pharmacologic class: Biguanide and Sulfonylurea.
Source: FDA drug label (Glipizide and Metformin Hydrochloride), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 1b18b903-eb52-4d08-b4a5-f984957eb116), via openFDA; the full label on DailyMed
Is there a generic for glipizide and metformin (Metaglip)?
The FDA approved the first generic glipizide and metformin on October 27, 2005. 6 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists glipizide and metformin from 9 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2002 earliest approval on file
- 2005 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for glipizide and metformin (Metaglip)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.242 per unit (Glipizide-metformin 2.5-250 mg), up 10% from $0.219 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Glipizide-metformin 5-500 mg (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Glipizide-metformin 2.5-250 mg | Generic | $0.242 per unit | n/a | +10% |
| Glipizide-metformin 2.5-500 mg | Generic | $0.221 per unit | n/a | -23% |
| Glipizide-metformin 5-500 mg | Generic | $0.202 per unit | n/a | -5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has glipizide and metformin been recalled?
The FDA's Enforcement Report lists 1 recall naming glipizide and metformin since 2015: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 25, 2015 | Class II | Heritage Pharmaceuticals, Inc. | Failed Impurities/Degradation Specifications: Out of specification for unknown impurity. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the glipizide and metformin label say about other medicines?
The glipizide and metformin label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Topiramate | warnings | … acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic … |
Source: FDA drug label (Glipizide and Metformin Hydrochloride), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 1b18b903-eb52-4d08-b4a5-f984957eb116), via openFDA; the full label on DailyMed
What do FAERS reports show for glipizide and metformin?
The FDA Adverse Event Reporting System holds 82 reports that list glipizide and metformin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3 are coded as a death and 21 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as glipizide and metformin?
20 other medicines are given the same way (oral) and in the same FDA class as glipizide and metformin or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Glimepiride | Type 2 diabetes | 29 labelers | $0.0507 per tablet 4 mg tablet | No current entry |
| Glyburide | Type 2 diabetes | 16 labelers | $0.0643 per tablet 5 mg tablet | A presentation being discontinued |
| Glimepiride and pioglitazone | Type 2 diabetes | none listed | $10.52 per unit 30-4 | No current entry |
| Pioglitazone | Type 2 diabetes | 22 labelers | $0.0675 per tablet 15 mg tablet | No current entry |
| Sitagliptin | Type 2 diabetes | 4 labelers | $3.77 per tablet 100 mg tablet | No current entry |
| Repaglinide | Type 2 diabetes | 7 labelers | $0.0987 per tablet 1 mg tablet | No current entry |
| Nateglinide | Type 2 diabetes | 9 labelers | $0.179 per tablet 60 mg tablet | No current entry |
| Acarbose | Type 2 diabetes | 6 labelers | $0.274 per tablet 100 mg tablet | No current entry |
Every medicine labeled for the same conditions as glipizide and metformin
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to glipizide and metformin
- 20 medicines for the same use
- Other biguanides
- the pharmacologic class, with prices and generics
- Glipizide and metformin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other